Press release
Steroid Refractory Acute GvHD Clinical Trial Pipeline Gains Momentum: 3+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Steroid Refractory Acute Graft Versus Host Disease Pipeline Report
*
In December 2025, Asian Institute of Gastroenterology, India announced a study is designed to explore whether the combination of infliximab and tofacitinib offers greater early clinical benefit compared to infliximab alone, tofacitinib alone for adults hospitalized with ASUC who do not respond to intravenous corticosteroids.The goal is to generate preliminary data that may inform future treatment approaches aimed at improving remission rates, accelerating mucosal healing, and reducing the need for colectomy in this high risk population.
*
DelveInsight's Steroid Refractory Acute Graft Versus Host Disease pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Steroid Refractory Acute Graft Versus Host Disease treatment.
*
The leading Steroid Refractory Acute Graft Versus Host Disease Companies such as MaaT Pharma, ReAlta Life Sciences Inc., Ironwood Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co. Ltd., and others.
*
Promising Steroid Refractory Acute Graft Versus Host Disease Pipeline Therapies such as Ruxolitinib, Tocilizumab, MC0518, ASC930, Neihulizumab (ALTB-168), Methoxsalen, Jaktinib Hydrochloride Tablets, ALPN-101, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Steroid Refractory Acute Graft Versus Host Disease Treatment Drugs [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Steroid Refractory Acute Graft Versus Host Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Steroid Refractory Acute Graft Versus Host Disease Pipeline Report also highlights the unmet needs with respect to the Steroid Refractory Acute Graft Versus Host Disease.
Steroid Refractory Acute Graft Versus Host Disease Overview
Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) is a severe and life-threatening complication that can occur after allogeneic hematopoietic stem cell transplantation (HSCT). Acute GVHD develops when donor immune cells recognize the recipient's tissues as foreign and initiate an inflammatory immune response. Corticosteroids are considered the first-line therapy; however, a significant proportion of patients fail to respond adequately, leading to the classification of steroid-refractory aGVHD.
Steroid Refractory Acute Graft Versus Host Disease Emerging Drugs Profile
*
MaaT013: MaaT Pharma
MaaT013 is an innovative, first-in-class, pooled allogeneic microbiome therapeutic developed by MaaT Pharma for treating steroid-refractory acute Graft-versus-Host Disease (SR-aGVHD). This therapeutic approach involves administering a standardized, carefully screened fecal microbiota preparation derived from multiple donors, designed to restore gut microbiome diversity and modulate immune responses in patients who have failed standard steroid treatments. It is a donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapy, containing Butycore, a group of bacterial species known to produce anti-inflammatory short-chain-fatty acids. MaaT013 has received Orphan Drug Designation from FDA and EMA. Currently, the drug is in Phase III stage of its development for the treatment of Steroid refractory acute graft-versus-host disease.
*
RLS-0071: ReAlta Life Sciences, Inc.
RLS-0071 (pegtarazimod) is an innovative investigational therapeutic candidate developed by ReAlta Life Sciences, Inc. for treating Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGvHD). Based on the company's unique EPICC peptide platform, RLS-0071 features a dual-targeting mechanism designed to modulate both complement and innate inflammatory pathways, offering a novel approach to addressing this serious post-transplantation complication. The drug has received Orphan Drug Designation and Fast Track Designation from the FDA. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Steroid refractory acute graft-versus-host disease.
The Steroid Refractory Acute Graft Versus Host Disease Pipeline Report Provides Insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Steroid Refractory Acute Graft Versus Host Disease with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Steroid Refractory Acute Graft Versus Host Disease Treatment.
*
Steroid Refractory Acute Graft Versus Host Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Steroid Refractory Acute Graft Versus Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Steroid Refractory Acute Graft Versus Host Disease market
Access DelveInsight's detailed report now! @ New Steroid Refractory Acute Graft Versus Host Disease Drugs [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Steroid Refractory Acute Graft Versus Host Disease Companies
MaaT Pharma, ReAlta Life Sciences Inc., Ironwood Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co. Ltd., and others.
Steroid Refractory Acute Graft Versus Host Disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Oral
*
Intravenous
*
Subcutaneous
*
Intramuscular
*
Molecule Type
Steroid Refractory Acute Graft Versus Host Disease Products have been categorized under various Molecule types such as
*
Monoclonal Antibody
*
Peptides
*
Small molecule
*
Product Type
Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Steroid Refractory Acute Graft Versus Host Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Steroid Refractory Acute Graft Versus Host Disease Pipeline Report
*
Coverage- Global
*
Steroid Refractory Acute Graft Versus Host Disease Companies- MaaT Pharma, ReAlta Life Sciences Inc., Ironwood Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co. Ltd., and others.
*
Steroid Refractory Acute Graft Versus Host Disease Pipeline Therapies- Ruxolitinib, Tocilizumab, MC0518, ASC930, Neihulizumab (ALTB-168), Methoxsalen, Jaktinib Hydrochloride Tablets, ALPN-101, and others.
*
Steroid Refractory Acute Graft Versus Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
*
Steroid Refractory Acute Graft Versus Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight's in-depth pipeline report today! @ Steroid Refractory Acute Graft Versus Host Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
*
Introduction
*
Executive Summary
*
Steroid Refractory Acute Graft-Versus-Host Disease : Overview
*
Pipeline Therapeutics
*
Therapeutic Assessment
*
Steroid Refractory Acute Graft-Versus-Host Disease - DelveInsight's Analytical Perspective
*
Late Stage Products (Phase III)
*
MaaT013: MaaT Pharma
*
Mid Stage Products (Phase II)
*
RLS-0071: ReAlta Life Sciences, Inc.
*
Early Stage Products (Phase I)
*
Preclinical and Discovery Stage Products
*
Inactive Products
*
Steroid Refractory Acute Graft-Versus-Host Disease Key Companies
*
Steroid Refractory Acute Graft-Versus-Host Disease Key Products
*
Steroid Refractory Acute Graft-Versus-Host Disease - Unmet Needs
*
Steroid Refractory Acute Graft-Versus-Host Disease - Market Drivers and Barriers
*
Steroid Refractory Acute Graft-Versus-Host Disease - Future Perspectives and Conclusion
*
Steroid Refractory Acute Graft-Versus-Host Disease Analyst Views
*
Steroid Refractory Acute Graft-Versus-Host Disease Key Companies
*
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=steroid-refractory-acute-gvhd-clinical-trial-pipeline-gains-momentum-3-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/steroid-refractory-acute-graft-versus-host-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Steroid Refractory Acute GvHD Clinical Trial Pipeline Gains Momentum: 3+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight here
News-ID: 4351904 • Views: …
More Releases from ABNewswire
Healthy for Wellness Has Given an In-Depth Analysis of Why CoreAge Rx Is Better …
Image: https://www.abnewswire.com/upload/2026/02/850d8bbc779e7d12fe40cc6941e07be3.jpg
Healthy for Wellness has published an in-depth analysis [https://healthyforwellness.com/healthy-for-wellness-has-given-an-in-depth-analysis-of-why-coreage-rx-is-better-than-its-competitors/]examining why CoreAge Rx stands out within the growing GLP-1 prescription weight management space. The review evaluates the company's physician-supervised structure, telehealth-based accessibility, compounded GLP-1 medication program, and patient-centered model in comparison to other providers operating in the same category.
CoreAge Rx [https://www.coreagerx.com/] operates as a prescription-based telehealth program that provides compounded GLP-1 medications for eligible adults seeking medically supervised weight management…
Healingxchange Spotlights CoreAge Rx as the Best GLP-1 Brand in the World, Citin …
Independent health platform credits CoreAge Rx's patient-centered approach, compounded GLP-1 therapies, and transparent pricing structure starting at $99 per month as the defining factors behind its top recognition
Image: https://www.abnewswire.com/upload/2026/02/7b94f9d607ddfdff3120e3788650d497.jpg
Healingxchange, an independent health and wellness platform, has published [https://www.healingxchange.com/meet-coreage-rx-the-best-glp-1-brand-in-the-world/] a featured review recognizing CoreAge Rx as the best GLP-1 brand in the world. The full article is available at www.healingxchange.com [http://www.healingxchange.com/]. The recognition follows a detailed editorial assessment of CoreAge Rx's…
CoreAge Rx Sweeps Independent GLP-1 Review Platforms in 2026, Earning Top Rankin …
From consumer watchdog sites to evidence-based medical platforms, CoreAge Rx has earned first-place recognition and top ratings across every major independent GLP-1 review published this year.
Image: https://www.abnewswire.com/upload/2026/02/07aff3d54bf8d86d80a25ed8afe9885f.jpg
CoreAge Rx, a physician-supervised telehealth weight management provider based in Wichita Falls, Texas, has earned top recognition from independent health and GLP-1 review platforms in 2026. Across evaluations covering as many as 78 competing providers, CoreAge Rx has consistently ranked first, collecting the highest…
5-Star Towing OKC Launches New Digital Hub to Redefine Oklahoma City Roadside As …
In a move to modernize the often-stressful experience of vehicle breakdowns, 5-Star Towing OKC has announced the launch of its newly redesigned website. The platform is set to become the new standard for Oklahoma City towing, offering unprecedented digital tools that put help directly into the hands of drivers.
The new website, found at www.247okctowing.com [http://www.247okctowing.com/], functions as a digital command center. It allows motorists to request a tow, jump-start, roadside…
More Releases for Steroid
Steroid Injections Market Qualitative Research on Growth & Opportunities Till 20 …
An exclusive Steroid Injections Market research report has been fabricated through the in depth analysis of the market dynamics across five regions including North America, Europe, South America, Asia-Pacific, Middle East and Africa. The segmentation of the market by components, end users, and region was done based on the thorough market analysis and validation through extensive primary inputs from industry experts (key opinion leaders of companies, and stakeholders) and secondary…
Endocrine Steroid Calibrator Market Size, Growth, Trends & Forecast 2030
Endocrine Steroid Calibrator Market: Primer
Reports and Insights deliver key insights on the Endocrine Steroid Calibrator Market. In terms of revenue, the endocrine steroid calibrator market is estimated to expand at a CAGR of **% during the forecast period, owing to numerous factors, regarding which Reports and Insights offer thorough insights and forecasts in its report on the endocrine steroid calibrator market.
To get Full Analysis report : https://reportsandinsights.com/report/endocrine-steroid-calibrator-market
Market Report Stance
The objective of this report on…
CrazyBulk Reviews 2021 - Natural Steroid Alternatives For Sale 2021
Get CrazyBulk From Its Official Website >> https://itsallabouthealth.net/crazybulk/
Bodybuilding is not just about building physical strength and exhausting one’s body inside the gym. It is an art, a game that requires a lot of patience, focus, and consistency, not just inside the gym but outside as well. Experts believe that people’s lifestyle and everyday routine is as important as their hard work in the gym. The phrase ‘you are what you…
Steroid-Corticosteroids Market Analysis 2018 Size, Share, Forecast 2023
Global Steroid-Corticosteroids market 2018 by Future Market Reports presents a professional and complete analysis of on the current Industry situation. The Global report includes Steroid-Corticosteroids Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Steroid-Corticosteroids market players and the future prospects from various angles in detail. Industry analysis is a assessment tool used by…
Nasal Steroid Market to Rear Excessive Growth During 2026
Nasal steroids are medicines that mainly contain corticosteroids. Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of the body. Nasal steroids are used to provide relief to the inflamed areas of the nose. Based on drug type, the global nasal steroid market can be segmented into beclomethasone, budesonide, fluticasone, triamcinolone, and others. The fluticasone drug segment is likely to expand at a significant pace…
Steroid Injections Market Progresses for Huge Profits During 2025
Steroid injections are used to treat conditions such as joint pain, arthritis, sciatica, and inflammatory bowel disease. Steroid injections contain cortisone and a numbing medicine. These are synthetic versions of hormones normally produced by adrenal glands, two small glands found above the kidneys. Steroid injections, also known as corticosteroid injections, are anti-inflammatory medicines. Short-acting steroids can give relief within hours and should last for at least a week. The primary…
